WOODCLIFF LAKE, N.J., Sept. 9 /PRNewswire/ -- Teva Women's Health, Inc. announced today the relaunch of www.CopewithMenopause.com, an online resource for women seeking tips and advice for their menopause symptoms and treatment options. The Web site was redesigned to provide more interaction and tools for consumers to learn about menopause, its impact on women's lives and helpful ways to cope with the transition into the menopause years.
The relaunch of CopewithMenopause.com is happening now, during Menopause Awareness Month, while menopause is in the forefront of women's minds. While many women accept that menopause is a part of life, CopewithMenopause.com provides a resource for women to gather information on menopause symptoms and tips for coping with the various stages of the transition. According to the recent Menopause Impact Survey, two-thirds of women report being unprepared for the symptoms and impact of menopause. CopewithMenopause.com is designed to help women become more knowledgeable on the transition and help address questions and concerns they may have.
"Every woman's experience going through menopause is different. So even a woman who has many friends to talk to may feel alone with what she is experiencing," says Susan Wysocki, WHNP, FAANP, President and CEO of the National Association of Nurse Practitioners in Women's Health. "It's important for there to be trusted resources available for women looking to understand what's happening to their bodies. CopewithMenopause.com is full of expert advice and tips, and features tools to help start the conversation between a woman and her healthcare provider about menopause symptoms and possible treatment options."
One of the unique features of the Web site is the Menopause Impact Tool. The Menopause Impact Tool is a questionnaire designed to help initiate dialog between women and their healthcare providers by assessing her menopause symptoms and the overall impact on her life. It also helps women improve the quality of the time they have with their healthcare provider during office visits. Women can use the tool and print a one-page analysis to be shared with their healthcare provider on their next office visit. Because every woman's symptoms and the impact of menopause on their life are different, it's important to discuss the overall impact of menopause with a healthcare provider.
CopewithMenopause.com will continue to be updated with new information and expert opinions. The Web site will remain dedicated to bridging the gap between women and their healthcare providers, as well as providing a destination for women coping with menopause.
About Duramed Pharmaceuticals, Inc. (Now Teva Women's Health, Inc.)
Duramed Pharmaceuticals, Inc., (now Teva Women's Health, Inc.) which develops and markets proprietary pharmaceutical products in North America, focuses primarily on products for women and emphasizes the development and marketing of products for reproductive and menopausal needs. Currently, Duramed markets 27 proprietary pharmaceutical products.
Duramed is a subsidiary of Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin(R), Lotrel(R) and Protonix(R), the current economic conditions, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the effects of competition on our innovative products, especially Copaxone(R) sales, dependence on the effectiveness of our patents and other protections for innovative products, the impact of consolidation of our distributors and customers, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, our ability to achieve expected results though our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the uncertainty surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, the regulatory environment and changes in the health policies and structures of various countries, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, our ability to successfully identify, consummate and integrate acquisitions, including the integration of Barr Pharmaceuticals, Inc., the potential exposure to product liability claims to the extent not covered by insurance, our exposure to fluctuations in currency, exchange and interest rates, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, our ability to enter into patent litigation settlements and the intensified scrutiny by the U.S. government, the termination or expiration of governmental programs and tax benefits, impairment of intangible assets and goodwill, environmental risks, and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission ("SEC").
|SOURCE Teva Women's Health, Inc.|
Copyright©2009 PR Newswire.
All rights reserved